Japanese Dose-Response Study of Rimonabant in Obese Patients

A Dose-Response Relationship Study of SR141716 in Obese Patients

The primary objective is to verify the dose-response relationship of rimonabant on body weight change.

The secondary objectives are to compare the effect of 3 doses of SR141716 to placebo, on body weight loss and on secondary criteria associated with comorbidities, and to evaluate the safety and the pharmacokinetics of SR141716.

Inclusion Criteria:

• Body Mass Index ≥25 kg/m²
• Viceral Fat Area ≥ 100 cm²
• Diet therapy for more than 8 weeks before start of the placebo observation period
• Stable weight (variation < ±3kg within 8 weeks before start of observation period)
• At least 2 criteria of the following 3 comorbidities: Impaired Glucose Tolerance or Type 2 diabetes, Dyslipidemia (hypertriglyceridemia and/or low HDL-choresterol), Hypertension